Trial Profile
A prospective, randomised, double-blind, placebo-controlled, parallel group dose ranging study in asthma patients in Iceland to assess the safety, tolerability and efficacy of the MLK inhibitor, CEP-1347
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 May 2011
Price :
$35
*
At a glance
- Drugs CEP 1347 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors deCODE genetics
- 05 Nov 2010 New trial record.